Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prevotella_monensin_time series

ABSTRACT: Prevotella bryantii B14 was cultivated with monensin. Growth was monitored over a period of 72h including frequent sampling of cells.

INSTRUMENT(S):

ORGANISM(S): Prevotella Bryantii B14

SUBMITTER: Jana Seifert

LAB HEAD: Prof. Jana Seifert

PROVIDER: PXD026057 | Pride | 2021-10-13

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	24h_0_A.raw	Raw
	24h_0_B.raw	Raw
	24h_0_C.raw	Raw
	24h_20_A.raw	Raw
	24h_20_B.raw	Raw

Items per page:

1 - 5 of 35

Similar Datasets

Prevotella monensin concentration

Project description:Prevotella bryantii B14 was cultivated with monensin. Growth was monitored over a period of 9h with a broad range of monensin concentrations.

2021-10-13 | PXD026085 | Pride

Prevotella bryantii B14 proteins from in vitro cultivation under various short-chain fatty acids (SCFA)

Project description:P. bryantii B14 cells were cultivated separately in acetic (Acet), propionic (Prop), butyric (But), iso-butyric (iBut), valeric (Val), iso-valeric (iVal) and 2-methyl butyric acid (2MB) as well as in a mixture of all mentioned short-chain fatty acids (Mix). All 8 treatments were analyzed regarding their proteomes in order to understand the requirements and effects of each SCFA on the metabolism.

2021-09-09 | PXD016407 | Pride

Cytotoxic and anti-Toxoplasma gondii activities of monensin on human brain microvascular endothelial cells

Project description:The aim of the present work was to investigate the effect of monensin on the in vitro growth of T. gondii tachyzoites and on the host cells (human brain microvascular endothelial cells - hBMECs). The hypotheses were that (1) inhibition of the WNT signalling pathway by monensin can reduce the growth of T. gondii infecting human brain microvascular endothelial cells (hBMECs) and (2) by suppression of the growth of T. gondii using monensin, impairment of the BBB integrity can be restored (3) inhibition of WNT pathway by monensin can be detected by microarray experiment.

2020-07-06 | E-MTAB-8817 | biostudies-arrayexpress

Project description:B14

| PRJEB45767 | ENA

Project description:Burkholderia sp. B14

| PRJEB18862 | ENA

C-terminal glycosylation of type IX secretion system cargo proteins in Prevotella intermedia bearing both short and long secretion signals

Project description:Prevotella intermedia is a Gram-negative bacterium that is notably linked to periodontitis and acute necrotizing ulcerative gingivitis. P. intermedia is known to utilise the T9SS to secrete and anchor virulence factors to the cell surface, presumably via C-terminal modification of the cargo protein with a cell surface polysaccharide. The identity of the linking sugar and the sites of modification on the cargo have yet to be determined. Here, we first employed Hidden Markov Models to predict cargo proteins in P. intermedia, and then conducted LC-MS/MS analyses of partially deglycosylated fractions to characterise the C-terminal glycosylation. A total of 80 cargo proteins were predicted based on the presence of a T9SS C-terminal domain signal (CTD), and these were divided into 48 short CTDs predicted by AlphaFold to adopt a single 3-stranded β-sheet and 32 long CTDs predicted to form the more typical larger β-sandwich structures. Cleavage sites for five short CTDs and four long CTDs were experimentally determined, and glycosylation was observed at the mature C-terminus of six cargo. Two glycans were identified of delta masses 419.198 and 433.185 Da, corresponding to novel linkages to N-alanyl dHex-HexNAc and N-alanyl (Me-dHex)-HexNAc, respectively, with the alanine amide-linked to the protein C-terminus. This indicated that both short and long CTDs were cleaved and glycosylated. AlphaFold multimer modelling predicted that both kinds of CTDs could bind to the PorV shuttle protein in the same manner, with the conserved CTD motifs interacting with the same sites in PorV.

2025-05-07 | PXD057272 | Pride

The HDAC inhibitor Givinostat modulates key hematopoietic genes in JAK2V617F cells, affecting proliferation, differentiation and apoptosis

Project description:We investigated the mechanism of action of the HDAC inhibitor Givinostat in JAK2V617F cells. We confirm that the drug inhibits colony formation and proliferation and induces apoptosis at doses 2-3 fold lower in JAK2V617F (HEL, UKE1 and SET2) compared to JAK2 wild type cell lines (K562, KU812, THP1 and KG1). By global gene expression analysis, we observed 293 common genes in HEL and UKE1 modulated at 6 hour by Givinostat (179 up and 114 down), of which 8/8 were validated by RTQ-PCR. 25, 28 and 33 modulated genes are implicated in the regulation of proliferation, apoptosis and hematopoiesis, respectively. Interestingly, 9 genes, known to be deregulated in MPN (myeloproliferative neoplasms) patients cells, were normalized by Givinostat. The hematopoietic transcription factors NFE2 and C-MYB were downmodulated by the drug specifically in JAK2V617F cells, and ETS1 was upregulated in all cell lines, at both the RNA and protein levels. Modulation of NFE2 and C-MYB was JAK2 dependent, as shown by use of the JAK2 inhibitor AG490. Finally, we suggest that the inhibition of NFE2 and induction of ETS1, also observed in freshly isolated CD34+ cells from MPN patients, may be at least in part responsible for the observed inhibition of erythroid differentiation by the drug. Gene expression profiling, JAK2V617F cell lines, ITF2357. This series of microarray experiments contains the gene expression profiles of independent triplicates of HEL and UKE1 erythroleukemia cell lines bearing the JAK2V617F mutation, before and after ITF2357 treatment. 100 nanograms of total RNA were processed, and fragmented biotin-labelled single-stranded DNA target was hybridized to the GeneChipÂ® Gene 1.0 ST array following the Affymetrix manufacturer's instructions.

2012-07-16 | E-GEOD-27615 | biostudies-arrayexpress

Microarray analysis of human A549 lung cancer cells treated with brefeldin A, golgicide A, monensin or vehicle control for 8 h or 20 h

Project description:A549 cells were treated for 8 or 20 h using 20 ng/mL brefeldin A (BFA), 5 ÂµM golgicide A (GCA), 10 ÂµM monensin (MON) or the appropriate vehicle control (BFA/EtOH, MON/EtOH, GCA/DMSO).

2017-12-18 | E-MTAB-5627 | biostudies-arrayexpress

X-Ray Exposure Induces Structural Changes in Human Breast Proteins

Project description:During radiotherapy, X-rays can deliver significant doses of ionising radiation to both cancerous and surrounding healthy tissues, often leading to undesirable side effects that compromise patient outcomes. While the cellular effects of such therapeutic x-ray exposures are well studied, the impact on extracellular matrix (ECM) proteins, which are critical to tissue integrity, remains poorly understood. This study characterises the response of breast proteins, including the major ECM components collagen I and fibronectin, to therapeutic X-rays doses of 50Gy (as employed in breast radiotherapy) and 100Gy, using a combination of gel electrophoresis, biochemical assays, and mass spectrometry-based peptide location fingerprinting (PLF) analysis. In purified protein solutions, X-ray exposure led to fragmentation of constituent α chains of collagen I, and in fibronectin localised structural modifications (as detected by LC-MS/MS peptide location fingerprinting [PLF]) which increased its binding affinity for collagen I. In complex environments, such as newly synthesised fibroblast-derived ECM (fECM) and mature ex vivo breast tissue, therapeutic x-rays induced proteolytic changes in, not just collagen I and fibronectin, but also key basement membrane proteins, including collagen IV, laminin, nidogen-1, and perlecan. Intracellular proteins associated with gene expression (RPS3, MeCP2), cytoskeleton (moesin, plectin), and the endoplasmic reticulum (calnexin) were also found to be structurally compromised. These structural changes may impair the ECM integrity and alter cell-ECM interactions, with potential implications for tissue stiffening, fibrosis, and impaired wound healing in irradiated tissues.

2025-06-28 | PXD060871 | Pride

Burkholderia sp. b14

Project description:Burkholderia sp. B14 genome sequencing

| PRJNA303197 | ENA